The Inflation Reduction Act could lower out-of-pocket costs by around $7.4 billion in 2025 for more than a third of all Americans enrolled in Medicare Part D, according to a ...

New re­search is look­ing to con­nect the dots be­tween di­rect-to-con­sumer (DTC) ad­ver­tis­ing and low­er clin­i­cal ben­e­fits or ther­a­peu­tic val­ue.

Phathom Pharmaceuticals is still working out the kinks of launching two already-approved drugs for a bacterial infection and snagging an NDA approval for another gastrointestinal indication after ...

Lat­est news on two FDA ap­provals; High-pro­file moves for John Reed, Brent Saun­ders, Christi Shaw..; and more ...

New data on an injectable form of Eisai's Alzheimer's drug, Leqembi, showed that it was more effective than an intravenous version at clearing amyloid but also came with a higher ...

Galderma’s annual push, and funding donation, for breast cancer awareness during October this year is focused on the personal stories of survivors who’ve used its aesthetics products to feel ...

Novo Nordisk spelled out how it will try to catch up with the extraordinary demand for its GLP-1 drugs, underscoring its rationale for its in-house API production and strategic fill ...

Eli Lilly will pay up to $1.925 billion in cash for weight loss drugmaker Versanis, marking the Big Pharma’s fourth acquisition this summer after deals for DICE Therapeutics, Sigilon and ...

The next generation of Operation Warp Speed is coming soon, and this time it's going to take aim at rare diseases, Peter Marks, the director of the FDA's Center for ...

Tech, com­merce-fo­cused in­vestor un­veils $500M bet on health­care ...

Vertex sued the federal government on Monday in an effort to expand its fertility support program to certain patients taking its new gene therapy for sickle cell disease and transfusion ...

French biotech Smart Immune has raised more than half of its roughly €50 million ($54 million) target in an ongoing Series A round, with an eye to completing Phase I ...